Original Article

The evaluation of Remdesivir Utilization pattern and its correlation with clinical indicators in hospitalized patients during COVID

Abstract

Background: In 2019 COVID became the cause of a pandemic, with approximately 500,000 deaths in six months worldwide. Remdesivir, the first drug approved by the U.S. Food and Drug Administration (FDA) for COVID-19 treatment, gained attention from numerous medical centers worldwide.
Objective:The consecutive waves of COVID-19 peaks in Iran, coupled with the lack of widespread vaccination, and high consumption leading to a shortage of Remdesivir in the country, prompted an investigation into the usage patterns of Remdesivir and its correlation with clinical indicators in hospitalized patients.
Method: A retrospective cross-sectional study was conducted using 390 patients' electronic records in seven different hospitals. Electronic records were reviewed and information was extracted under four categories: demographic data, lab test results at admission, medication information, and lab test results after completing treatment. Patients were classified into three time periods based on the date of their first Remdesivir injection. Outcomes were defined as final clinical status and length of stay in hospital.
Results: A total of 390 patients were enrolled, with 198 females and 192 males. The longest hospital stay was 88 days, with an average of 7.5 days. A total of 1,979 doses of Remdesivir were prescribed, with 224 doses being in accordance with the national protocol, 22 doses exceeding the protocol, and 144 doses below the protocol. The overall average dose consumption was 5.07 for each patient.
Conclusion: Overall pattern of Remdesivir utilization in the hospitals evaluated in this study (affiliated with Shahid Beheshti University of Medical Sciences) has been reasonable and in accordance with national protocols for COVID-19 infection.

1. Coronavirus (COVID-19) events as they happen. cited in 5/24/2023 URL: https://www.fda.gov/news events/press-announcements/covid-19-update-fda broadens-emergency-use-authorization-veklury remdesivir-include-all-hospitalized
2. Bourgonje AR, Abdulle AE, Timens W, et al.Angiotensin-converting enzyme 2 (ACE2), SARS CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). J Pathol. 2020;251(3):228-248.
3. Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, Hall MD. Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19. ACS Cent Sci. 2020;6(5):672-683.
4. FDA Approves First Treatment for COVID-19 | FDA. cited in 5/24/2023 URL: https://www.fda.gov/news events/press-announcements/fda-approves-first treatment-covid-19
5. COVID-19 Update: FDA Broadens Emergency Use Authorization for Veklury (remdesivir) to Include All Hospitalized Patients for Treatment of COVID-19 FDA.
6. Mehellou Y, Rattan HS, Balzarini J. The ProTide Prodrug Technology: From the Concept to the Clinic. J Med Chem. 2018;61(6):2211-2226.
7. Slusarczyk M, Serpi M, Pertusati F. Phosphoramidates and phosphonamidates (ProTides) with antiviral activity. Antivir Chem Chemother. 2018;26:2040206618775243.
8. Last Edition of National COVID guidelines | URL: https://irimc.org/news/id/49153
9. Chaokromthong K, Sintao N. Sample size estimation using Yamane and Cochran and Krejcie and Morgan and green formulas and Cohen statistical power analysis by G* Power and comparisions. Apheit International Journal, 2021;10(2):76-86.
10. van Paassen J, Vos JS, Hoekstra EM, Neumann KMI, Boot PC, Arbous SM. Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes. Crit Care. 2020;24(1):696.
11. Wagner C, Griesel M, Mikolajewska A,et al. Systemic corticosteroids for the treatment of COVID-19. Cochrane Database Syst Rev. 2021;8(8):CD014963.
12. Crichton ML, Goeminne PC, Tuand K,et al; European Respiratory Society COVID-19 Task Force. The impact of therapeutics on mortality in hospitalised patients with COVID-19: systematic review and meta-analyses informing the European Respiratory Society living guideline. Eur Respir Rev. 2021;30(162):210171.
13. Mojtabavi H, Saghazadeh A, Rezaei N. Interleukin-6 and severe COVID-19: a systematic review and meta analysis. Eur Cytokine Netw. 2020;31(2):44-49.
Files
IssueVol 11, No 4 (Autumn 2023) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/jpc.v11i4.16020
Keywords
COVID-19 Remdesivir Drug utilization pattern Cross-sectional study
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Soroush Y, Esmaily H, Ghalandari N. The evaluation of Remdesivir Utilization pattern and its correlation with clinical indicators in hospitalized patients during COVID. J Pharm Care. 2023;11(4):226-232.